Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing immuno-oncology therapies. The company’s approved product, LOQTORZI (toripalimab-tpzi), is an anti-PD-1 monoclonal antibody indicated for the treatment of nasopharyngeal carcinoma in the United States and Canada. LOQTORZI was developed in collaboration with Junshi Biosciences and is the only FDA-approved immune checkpoint inhibitor commercially available in the U.S. for these indications. The company’s pipeline includes two mid-stage clinical candidates targeting the tumor microenvironment: casdozokitug (CHS-388), an investigational antibody targeting IL-27 under evaluation for hepatocellular carcinoma, and tagmokitug (CHS-114), an afucosylated antibody targeting CCR8 under evaluation for head and neck squamous cell carcinoma and other solid tumors. Coherus Oncology commercializes LOQTORZI in the United States and holds global rights to develop and commercialize its pipeline candidates. The company is executing an initiative to onshore the biomanufacturing processes for its products to the United States. Formerly known as Coherus BioSciences, Inc., the company changed its name in May 2025 following the divestiture of its biosimilar businesses to reflect its exclusive focus on immuno-oncology medicines.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage coherus.com
Sector Healthcare IR page investors.coherus.com
Tags
immuno-oncology, anti-pd-1, nasopharyngeal carcinoma, hepatocellular carcinoma, head and neck cancer, monoclonal antibodies, tumor microenvironment, clinical-stage pipeline, LOQTORZI, toripalimab-tpzi, casdozokitug, CHS-388, SRF388, tagmokitug, CHS-114, SRF114, Junshi Biosciences, Apotex
Press page —

Metrics

Valuation  
Market cap $ 186.987M
Market cap (USD) $ 186.987M
P/E -1.08
PEG —
P/BV 7.41
P/S 3.49
P/OCF -1.08
P/FCF -1.35
Dividend yield —
Turnover / mcap —
Returns  
ROE 275.4%
ROI 171.3%
ROIC -138.5%
Profit margin 398.4%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 60.7%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 6
Quality score -29.4%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 42.172M 266.96M 257.244M 211.042M 326.551M 475.824M 356.071M 0 1.556M 190.106M 30.041M 31.106M 2.751M
Net profit 168.024M 28.507M -237.892M -291.754M -287.1M 132.244M 89.833M -209.339M -238.17M -127.337M -223.26M -87.133M -53.635M
Free cash flow -138.513M -20.44M -175.17M -243.163M -38.721M 146.914M 26.533M -160.055M -204.859M -259.06M -114.154M -26.776M 15.05M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 1.42 1.38 3.33 7.92 15.96 17.38 18 9.05 8.8 28.15 22.96 16.32 —
Price performance 12m 0.03 -0.59 -0.58 -0.5 -0.08 -0.03 0.99 0.03 -0.69 0.23 0.41 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 1.86M — 0.00 142M 157M 123M 110M 261M 111M 17.8M
↳ YoY growth +19.2% +10.6% -21.7% -10.6% +136.9% -57.3% -84.0%
↳ 5y CAGR +125.8% +151.5% +131.3% -4.8% -35.3%
Lease liabilities (USD) — — 9.2M 12.5M 13.1M 10.7M 9.36M 7.47M 4.98M 3.29M
Cash and deposits (USD) 125M 127M 72.4M 178M 541M 417M 63.5M 103M 126M 88.9M
Intangible assets (USD) 2.62M 2.62M 2.62M 2.62M 2.62M 2.62M 5.93M 71.7M 24.8M 20M
Right-of-use assets (USD) — — 7.2M 10.6M 9.96M 8.19M 5.69M 5.91M 4.52M 2.95M
Cash flow detail
Operating cash flow (USD) -253M -200M -159M 28.4M 154M -37.4M -241M -175M -20.4M -139M
Purchases of property, plant and equipment (USD) -6.52M -4.57M -789,000 -1.82M -7.23M -1.29M -2.04M -286,000 — —
Change in receivables (cash effect) (USD) -299,000 1.86M 0.00 -142M -15.2M 34.1M 13.1M -151M 149M 93.6M
Change in inventories (cash effect) (USD) — 0.00 -5.48M -48.2M -36.2M -6.25M -47.3M -46.7M -32M -17.1M
Change in payables (cash effect) (USD) -4.97M -3.81M -301,000 — — — — — — —
Interest paid (cash effect) (USD) -6.94M -8.2M -8.2M -15.3M -17M -18.7M -34.9M -37.9M -25.4M -9.92M
Income taxes paid (cash effect) (USD) — 0.00 0.00 -1.73M -3.95M -1.22M -40,000 118,000 114,000 -36,000
Share-based compensation (USD) 27.4M 33.4M 34.8M 33.6M 38.2M 51.4M 50.7M 43.1M 27.8M 17M
Operating cash flow before change in receivables (USD) -252M -202M -159M 170M 169M -71.5M -254M -24.2M -170M -232M
Free cash flow (OCF - PPE - intangibles) (USD) -259M -205M -160M 26.5M 147M -38.7M -243M -175M — —
Income detail
Research and development expense (USD) 254M 162M 110M 94.2M 143M 363M 199M 109M 93.3M 109M
↳ 5y CAGR +36.0% +28.7% +3.8% -7.7% +7.4% +4.2% -0.1% -0.2% -5.3%
Total comprehensive income (USD) -128M -238M -209M 89.6M 133M -287M -292M -238M 28.5M 168M
Comprehensive income to owners (USD) -128M -238M -209M 89.6M 133M — — — — —
Provision for credit losses (USD) -1.3M — — — — — — — — —
Credit cost ratio (credit losses / average receivables) (%) 76.0% — — — — — — — — —
Reported Mar 14, 2017 Feb 27, 2020 Feb 27, 2020 Feb 27, 2020 Feb 25, 2021 Feb 23, 2022 Mar 6, 2023 Mar 15, 2024 Mar 17, 2025 Mar 9, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

– Focus development efforts on tagmokitug/toripalimab as a potential best-in-disease treatment for esophageal cancer with plans for expedited development –

– Deprioritize development of tagmokitug/toripalimab in other indications to allocate resources toward advancing the lead indication –

– Right-sizing reduces headcount by ~30%, aligning organization with forward-focused needs –

– Reports LOQTORZI® net revenue of $14.0 million in Q3 2026 –

– Conference call today at 5:00 p.m. Eastern Standard Time –

REDWOOD CITY, Calif., November 9, 2026 -- Coherus Oncology, Inc. (Nasdaq: CHRS) today reported financial results for the third quarter 2026 and provided an overview of recent business highlights.

“The strategic prioritization of esophageal cancer as our best-in-disease focus for tagmokitug, together with the Transition Services Agreement wind-down and the toripalimab process transfer completion, provides an ideal opportunity to right-size the organization and deliver financial benefits that flow directly from this prioritization,” said Denny Lanfear, Chief Executive Officer of Coherus Oncology.

Oct 28, 2026

PDF Version

-1L ESCC confirmed ORR of 75% irrespective of PD-L1 status, confirmed ORR of 100% for PD-L1- positive, in evaluable patients-

-2L ESCC durable clinical benefit observed with a clear dose-response irrespective of PD-L1 status and in PD-1 refractory patients-

  • Anti-tumor activity demonstrated across five indications and over 120 patients, including HPV-positive head and neck and GI tumors-

  • Acceptable and manageable safety profile, with no new safety signals to date supports continued development-

  • Company to host a webcast today at 4:30 pm EDT-

REDWOOD CITY, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc.(Nasdaq: CHRS) today announced interim clinical data from the TREGCHECK™ development program evaluating tagmokitug, its investigational cytolytic CCR8 antibody, in combination with toripalimab, with or without chemotherapy. Tagmokitug-based treatment demonstrated encouraging anti-tumor activity across multiple solid tumors, including responses and durable disease stabilization in pretreated and immunotherapy-resistant patients. In evaluable front-line esophageal squamous cell carcinoma (ESCC) patients, tagmokitug in combination with toripalimab and chemotherapy demonstrated a confirmed overall response rate (cORR) of 75% irrespective of PD-L1 status, and a cORR of 100% in PD-L1 positive patients as of October 14, 2026. Subsequent to the data cutoff date, two additional partial responses were confirmed, increasing the cORR to 89% of the evaluable patient dataset.

Activity and duration of response in second-line ESCC patients, as well as an acceptable and manageable safety profile, support the selected dose and expansion of enrollment in both ESCC cohorts.

“The totality of these interim data provides clinical proof of concept for tagmokitug, strengthens our confidence in the selected go-forward dose, and integrated development strategy. We are particularly encouraged by the compelling clinical activity and manageable tolerability observed in ESCC, a disease where significant unmet medical need remains. We look forward to the continued maturation and expansion of these data across both first and second-line ESCC, as we advance the development of tagmokitug for patients with difficult-to-treat cancers,” said Rosh Dias, M.D., Chief Medical Officer, Coherus Oncology.

“These clinical data represent the potential for a meaningful advancement in ESCC, where there is a significant underserved patient population,” said Dan Feng, M.D., Ph.D., Assistant Professor of Medicine, Hematology and Medical Oncology, at the Icahn School of Medicine at Mount Sinai. “Esophageal cancer is a devastating disease, with limited treatment options. I am particularly impressed with the front-line response rate observed with the tagmokitug combination with a PD-1 inhibitor and chemotherapy. I am encouraged by the manageable and acceptable safety profile observed with tagmokitug in combination with toripalimab with and without chemotherapy.”

“This encouraging clinical evidence supports our strategy of targeting CCR8-positive regulatory T cells to overcome immune resistance in cancer, and underscores Coherus Oncology’s scientific leadership in the emerging field of CCR8 Treg depletion,” said Denny Lanfear, Chief Executive Officer of Coherus Oncology. “Importantly, the strength of the emerging ESCC data provides a clear and efficient path for advancing the development of tagmokitug in esophageal cancer across both indications. Toripalimab is already established as a first-line treatment for ESCC in ex-US major markets, including Europe and China. Given the significant burden of this disease globally, particularly in Asia, we believe these results further strengthen the strategic and global development opportunity for tagmokitug.”

Key Interim Findings The totality of the interim clinical activity, dose-response findings and safety observations support continued development of tagmokitug and expansion of the first-line and second-line ESCC cohorts.

First-Line ESCC: Phase 1b TREGCHECK 102 Cohort C

**Study design.**Patients with previously untreated advanced or metastatic ESCC received tagmokitug 700 mg plus toripalimab, 5-fluorouracil and cisplatin. The primary endpoint is safety; secondary endpoints include ORR, duration of response, clinical benefit rate and progression-free survival. As of October 14, 2026, 10 patients were safety evaluable and 8 were efficacy evaluable, and enrollment is ongoing. Of the evaluable patient data set:

| Efficacy Measure | Interim Result | Key Considerations |

| cORR all comers | 75% (6/8) | No PD-1 inhibitors approved in PD-L1-negative ESCC in the US |

| Post-data-cutoff cORR | 89% (8/9) | Includes confirmation of a prior unconfirmed partial response (uPR) and one newly evaluable patient with a confirmed partial response (cPR) |

| Confirmed ORR in PD-L1 positive ESCC | 100% | US SoC Benchmark (PD-1 + chemo) cORR is 44%-59% for PD-L1 positive ESCC |

| Confirmed complete response | 1 patient | Confirmed at the data cutoff |

| |

Figure 1

First-line ESCC waterfall plot from TREGCHECK 102 Cohort C. Data as of October 14, 2026

Figure 1. First-line ESCC waterfall plot from TREGCHECK 102 Cohort C. Data as of****October 14, 2026

Second-Line ESCC: Phase 1b TREGCHECK 102 Cohort B

**Study design.**Patients with recurrent or metastatic ESCC who failed first-line systemic chemotherapy with or without a PD-1 inhibitor were randomized 1:1 to tagmokitug 300 mg or 700 mg plus toripalimab. As of October 14, 2026, 17 patients were safety evaluable and 8 (2 in 300 mg and 6 in 700 mg) were efficacy evaluable and enrollment is ongoing. Of the evaluable patient data set:

| Efficacy Measure | Interim Result | Key Considerations |

| Clinical Benefit Rate (CBR) in 700 mg tagmokitug dose arm | 33.3% (2/6) | Consistent with immuno-oncology-driven durable stable disease (SD) |

| cORR in 700mg tagmokitug dose arm | 16.7% (1/6) | Confirmation of 1 PR and 1 uPR |

| Median Progression-Free Survival (mPFS) in 700mg tagmokitug dose arm | 5.5 months | US SoC Benchmark (chemo) mPFS is ~3.4 months |

| |

Figure 2

Second-line ESCC swimmer plot by randomized tagmokitug dose. Data as of October 14, 2026

Figure 2. Second-line ESCC swimmer plot by randomized tagmokitug dose.Data as ofOctober 14, 2026

Interim Results in Other Indications

| Cohort | Population | Interim findings |

| 2L HNSCC Two tagmokitug doses (700 mg and 300 mg) plus toripalimab | 43 treated; 23 HPV-positive efficacy evaluable | In HPV-positive disease across doses, 13.0% cORR (3/23) and 26.1% CBR (6/23); Additional potential enrichment strategy based on Tumor Immune Regulatory Index (TIRI), a tumor-derived CCR8- containing biomarker score, under evaluation; HPV+ - TIRI+ patients demonstrated a 45% CBR (5/11). |

| 2L Upper GI: GC/GEJ/EAC Two tagmokitug doses (700 mg and 300 mg) plus toripalimab | 40 treated; 33 efficacy evaluable | At 700 mg, 4 confirmed PRs among 17 evaluable patient data set (23.5% cORR), including 2 PRs in EAC with follow- up continuing; Clear dose-response; Demonstrated PD-1 resistance rescue at 700 mg and tumor shrinkage in PD-1-refractory and naive patients; Durable clinical benefit with a chemo-free regimen. |

| 4L+ NLM MSS CRC 700 mg tagmokitug dose plus toripalimab | 20 treated; 17 efficacy evaluable | 5.9% cORR and 11.8% CBR, with antitumor activity and molecular response (ctDNA) observed in a highly refractory, IO-nonresponsive population with follow-up continuing. |

| |

Safety and Tolerability Tagmokitug demonstrated a manageable safety profile across the TREGCHECK™ clinical program. In 33 patients with monotherapy, no dose-limiting toxicities were observed through the 1200 mg every-three-week dose level, and no Grade 5 treatment-related adverse events were reported.

In more than 120 patients treated with tagmokitug in combination with toripalimab, no new safety signals beyond those associated with PD-1/immune checkpoint inhibitor therapy were identified. Most adverse events were Grade 1 or 2 and resolved, and safety was comparable across tagmokitug dose levels. Among 120 patients treated with tagmokitug plus toripalimab, the overall rate of immune-related adverse events (irAEs) was 40% (for all grades), with 20% experiencing Grade 3-5 irAEs. The most commonly reported TRAEs were infusion-related reactions (25.0%), fatigue (19.2%) and rash (15.8%). No Grade 5 treatment-related adverse events were reported.

In the first-line ESCC cohort, 10 patients treated with tagmokitug in combination with toripalimab and chemotherapy demonstrated a manageable safety profile, with no new safety signals or Grade 5 treatment-emergent adverse events observed. Most adverse events were attributed to chemotherapy and the treatment discontinuation rate is similar to the approved regimens for PD-1 inhibitors with chemotherapy.

Tagmokitug is an investigational product candidate and has not been approved by the U.S. Food and Drug Administration or any other regulatory authority. Its safety and efficacy have not been established.

Toripalimab is an investigational product candidate in these indications in the United States.

Clinical Development and Next Steps Based on the interim findings, Coherus plans to expand enrollment in first-line and second-line ESCC and continue to evaluate the durability of response, progression-free survival and biomarker findings across indications as the data mature.

Coherus is also advancing tagmokitug in combinations beyond PD-1 inhibition, including a planned study evaluating the safety of tagmokitug with a T-cell engager in mCRPC.

Webcast Information When: Wednesday, October 28, 2026, from 4:30 p.m. to 6:00 p.m. Eastern Daylight Time. To access the webcast, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: https://register-conf.media-server.com/register/BI40122fadb7e849969b28a667a784d035.

Webcast: https://edge.media-server.com/mmc/p/wygfpdac.

A live and archived webcast will be available on the “Investors” section of the Coherus website and accompanying materials will be available after the webcast at https://investors.coherus.com/events-presentations. Please log in approximately 15 minutes before the start of the webcast to ensure a timely connection.

Disclosure Information Coherus uses the https://investors.coherus.com website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

About Tagmokitug Tagmokitug is an investigational monoclonal antibody that selectively targets CCR8, a receptor highly enriched on regulatory T cells within the tumor microenvironment. Tagmokitug is currently being evaluated in Phase 1b/2a clinical trials (TREGCHECK™ 101: NCT05635643; TREGCHECK™ 102: NCT06657144) in patients with solid tumors in combination with the PD-1 inhibitor toripalimab and chemotherapy. It is part of Coherus Oncology’s next-generation immunotherapy pipeline being evaluated across multiple solid tumor settings.

About Coherus Oncology

Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation programmed death receptor-1 (“PD-1”) inhibitor, LOQTORZI® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, prostate, head and neck, colorectal and other cancers. The Company’s strategy is to grow sales of LOQTORZI in R/M Nasopharyngeal Carcinoma and advance the development of its two pipeline candidates in combination with LOQTORZI and through strategic partnerships.

Coherus’ innovative oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and improve outcomes for patients with cancer. Tagmokitug is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1b/2a studies in patients with advanced solid tumors; including head and neck squamous cell carcinoma, colorectal cancer, gastric, gastroesophageal junction, esophageal adenocarcinoma and esophageal squamous cell carcinoma. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in a Phase 2 study in patients with first-line hepatocellular carcinoma.

LOQTORZI® is a registered trademark of Coherus Oncology, Inc. ©2026 Coherus Oncology, Inc. All rights reserved.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this presentation and any accompanying commentary from the management of Coherus Oncology, Inc. (“Coherus”) are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this presentation may be identified by the use of words such as “anticipate,” “may,” “will,” “should,” “expect,” “could,” “intend,” “project,” “target,” “estimate,” “predict,” or “potential” or the negative of these terms or other similar expressions. These statements include, but are not limited to statements about the development plan for tagmokitug; ability of any of Coherus’s pipeline product candidates to be first-to-market, first-to-data or first in-class or best in class; the initiation, timing and progress of preclinical and clinical studies; future data readouts or catalysts based on the clinical trials of Coherus; market size, market value, addressable market or opportunity and the number of patients or incidence for particular indications; standard of care expectations; future collaborations; the degree of unmet need for particular indications; and the assumptions underlying or relating to such statements.

Such forward-looking statements involve substantial risks and uncertainties that could cause Coherus’s actual results, performance or achievements to differ significantly from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among other things, the risks and uncertainties inherent with clinical research and commercialization; the risks and uncertainties of the clinical development and regulatory approval process; risks related to Coherus’s ability to increase sales of LOQTORZI or expand LOQTORZI into other indications; the risk that Coherus is unable to complete commercial transactions in a timely manner or at all; risks and uncertainties in executing collaboration agreements and other joint ventures, including particular risks of working with international partners; the risk of Coherus’s dependence on an ability to raise funds, which may not be available on acceptable terms or at all; the risks and uncertainties of the degree of market acceptance for Coherus’s product and product candidates by physicians, healthcare providers and patients; and the risks and uncertainties of litigation. For a further discussion of these and other factors that could cause Coherus’s future results to differ materially from any forward-looking statements see the section entitled “Risk Factors” in Coherus’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the Securities and Exchange Commission (“SEC”) on August 5, 2026, as updated by Coherus’s subsequent reports filed with the SEC. Any forward-looking statements speak only as of the date of this presentation and are made based on the current plans, estimates, good faith beliefs and judgments of Coherus management, and the reader is cautioned not to rely on any forward-looking statements made by Coherus. Unless required by law, Coherus is not under any duty and undertakes no obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, of new information, data or methods, future events or other changes. Coherus’s past performance should not be considered to be a guarantee of future results.

Coherus Oncology Contact Information:

For Investors: Carrie Graham Vice President, Investor Relations & Advocacy [email protected]

Photos accompanying this announcement are available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a74251b2-e772-4b97-a5d7-f8d8299ee475 https://www.globenewswire.com/NewsRoom/AttachmentNg/643f09d5-29ea-44c3-b9ce-c78196e9209d

Primary Logo

Figure 1

First-line ESCC waterfall plot from TREGCHECK 102 Cohort C. Data as of October 14, 2026
Figure 2

Second-line ESCC swimmer plot by randomized tagmokitug dose. Data as of October 14, 2026

Oct 27, 2026

PDF Version

REDWOOD CITY, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc.(NASDAQ: CHRS), today announced that the company will be webcasting its participation in the following upcoming investor conferences:

  • Guggenheim 3rd Annual Healthcare Innovation Conference in Boston, MA on Tuesday, November 10, 2026, at 7:30 a.m. Eastern Daylight Time.

  • Jefferies Global Healthcare Conference in London, UK on Monday, November 16, 2026, at 10:30 a.m. Greenwich Mountain Time / 5:30 a.m. Eastern Daylight Time

The presentations will be accessible via webcast links on the Investor Events section of the Coherus website: https://investors.coherus.com/events-presentations. Replays of the presentations will be available for 30 days.

If you would like to request a one-on-one meeting with company management during the conferences, please reach out to your respective bank representative.

Disclosure Information

Coherus uses the https://investors.coherus.com website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

About Coherus

Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation programmed death receptor-1 (“PD-1”) inhibitor, LOQTORZI® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, prostate, head & neck, colorectal and other cancers. The Company’s strategy is to grow sales of LOQTORZI in R/M Nasopharyngeal Carcinoma and advance the development of its two pipeline candidates in combination with LOQTORZI and through strategic partnerships.

Coherus’ innovative oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and improve outcomes for patients with cancer. Tagmokitug is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1b/2a studies in patients with advanced solid tumors; including head and neck squamous cell carcinoma, colorectal cancer, gastric, gastro-esophageal-junction, esophageal adenocarcinoma and esophageal squamous cell carcinoma. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in a Phase 2 study in patients with first-line hepatocellular carcinoma.

LOQTORZI® is a registered trademark of Coherus Oncology, Inc. ©2026 Coherus Oncology, Inc. All rights reserved.

Coherus Oncology Contact Information:

For Investors:

Carrie Graham Vice President, Investor Relations & Advocacy [email protected]

Primary Logo

Prompts

Coherus Oncology, Inc. (ticker CHRS), listed in United States.

Company History

Date Change Detail
May 30, 2025 Renamed COHERUS BIOSCIENCES, INC. → COHERUS ONCOLOGY, INC.
Jan 14, 2013 Renamed BioGenerics, Inc. → COHERUS BIOSCIENCES, INC.